Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells
Published version of a preprint
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The Bcl-2 family protein Mcl-1 is often degraded in cancer cells subjected to effective therapeutic treatment, and defective Mcl-1 degradation has been associated with intrinsic and acquired drug resistance. However, a causal relationship between Mcl-1 degradation and anticancer drug responses has not been directly established, especially in solid tumor cells where Mcl-1 inhibition alone is insufficient to trigger cell death. In this study, we present evidence that Mcl-1 participates directly in determining effective therapeutic responses in colon cancer cells. In this setting, Mcl-1 degradation was induced by a variety of multikinase inhibitor drugs, where it relied upon GSK3β phosphorylation and FBW7-dependent ubiquitination. Specific blockade by genetic knock-in (KI) abolished apoptotic responses and conferred resistance to kinase inhibitors. Mcl-1-KI also suppressed the antiangiogenic and anti-hypoxic effects of kinase inhibitors in the tumor microenvironment. Interestingly, these same inhibitors also induced the BH3-only Bcl-2 family protein PUMA, which is required for apoptosis. Degradation-resistant Mcl-1 bound and sequestered PUMA from other prosurvival proteins to maintain cell survival, which was abolished by small-molecule Mcl-1 inhibitors. Our findings establish a pivotal role for Mcl-1 degradation in the response of colon cancer cells to targeted therapeutics, and they provide a useful rational platform to develop Mcl-1–targeting agents that can overcome drug resistance. Cancer Res; 77(9); 2512–21. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MCL1 can still limit the activity of Bcl-xL inhibitors and other chemotherapeutic agents in CRC [17–19]”
From MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma (2022) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“For example, the multi-kinase inhibitor regorafenib (Stivarga) and its analog sorafenib (Nexavar) are used to treat chemotherapy-resistant and metastatic colorectal cancer (CRC) and other gastrointestinal malignancies (13,14).”
BackgroundDirect observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419 · cited 5×
“PLA was performed using the Duolink In Situ Redstarter Kit (Sigma) according to the manufacturers’ instructions.”
BackgroundInfluentialWilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“Regorafenib and sorafenib inhibit kinases involved in mitogenic signaling and tumor angiogenesis, including CRAF, BRAF, VEGFRs, PDGFR, and c-KIT (15,16).”
BackgroundThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881 · cited 2×
“Stress-induced Mcl-1 degradation is mediated by its phosphorylation (26).”
BackgroundDeubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Many players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421 · cited 2×
“Stress-induced apoptosis in mammalian cells is regulated by the Bcl-2 family proteins through a series of orderly events, including mitochondrial outer membrane permeabilization (MOMP), cytosolic release of mitochondrial proteins such as cytochrome c, and activation of caspases (1,2).”
BackgroundStructure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501258m · Cited by 164
Research works printed but not linked: 40
- Bhola, 2016, Mitochondria-judges and executioners of cell death sentences, Mol Cell, 61, 695, 10.1016/j.molcel.2016.02.019 · DOI · Paper page
- Thomas, 2010, Mcl-1; the molecular regulation of protein function, FEBS Lett, 584, 2981, 10.1016/j.febslet.2010.05.061 · DOI · Paper page
- Perciavalle, 2013, Delving deeper: MCL-1′s contributions to normal and cancer biology, Trends Cell Biol, 23, 22, 10.1016/j.tcb.2012.08.011 · DOI · Paper page
- Mojsa, 2014, Mcl-1 ubiquitination: unique regulation of an essential survival protein, Cells, 3, 418, 10.3390/cells3020418 · DOI · Paper page
- Zhong, 2005, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis, Cell, 121, 1085, 10.1016/j.cell.2005.06.009 · DOI · Paper page
- Ding, 2007, Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization, Mol Cell Biol, 27, 4006, 10.1128/MCB.00620-06 · DOI · Paper page
- Inuzuka, 2011, SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction, Nature, 471, 104, 10.1038/nature09732 · DOI · Paper page
- Wertz, 2011, Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7, Nature, 471, 110, 10.1038/nature09779 · DOI · Paper page
- Opferman, 2005, Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells, Science, 307, 1101, 10.1126/science.1106114 · DOI · Paper page
- Fernandez-Marrero, 2016, Survival control of malignant lymphocytes by anti-apoptotic MCL-1, Leukemia, 30, 2152, 10.1038/leu.2016.213 · DOI
- Wilhelm, 2008, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Mol Cancer Ther, 7, 3129, 10.1158/1535-7163.MCT-08-0013 · DOI · Paper page
- Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
- Abou-Elkacem, 2013, Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model, Mol Cancer Ther, 12, 1322, 10.1158/1535-7163.MCT-12-1162 · DOI · Paper page
- Tong, 2017, FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation, Oncogene, 36, 787, 10.1038/onc.2016.247 · DOI · Paper page
- Yu, 2003, PUMA mediates the apoptotic response to p53 in colorectal cancer cells, Proc Natl Acad Sci U S A, 100, 1931, 10.1073/pnas.2627984100 · DOI · Paper page
- Abulwerdi, 2014, A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo, Mol Cancer Ther, 13, 565, 10.1158/1535-7163.MCT-12-0767 · DOI · Paper page
- Abulwerdi, 2014, 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation, J Med Chem, 57, 4111, 10.1021/jm500010b · DOI
- Peng, 2013, Targeting Bax interaction sites reveals that only homo-oligomerization sites are essential for its activation, Cell Death Differ, 20, 744, 10.1038/cdd.2013.4 · DOI
- Yu, 2006, PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation, Clin Cancer Res, 12, 2928, 10.1158/1078-0432.CCR-05-2429 · DOI
- Ming, 2006, PUMA dissociates Bax and BCL-XL to induce apoptosis in colon cancer cells, J Biol Chem, 281, 16034, 10.1074/jbc.M513587200 · DOI · Paper page
- Dudgeon, 2012, Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3beta and NF-kappaB to suppress tumor cell growth, Oncogene, 31, 4848, 10.1038/onc.2011.644 · DOI
- Chen, 2014, Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis, Clin Cancer Res, 20, 3472, 10.1158/1078-0432.CCR-13-2944 · DOI
- Dudgeon, 2010, PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01, Mol Cancer Ther, 9, 2893, 10.1158/1535-7163.MCT-10-0635 · DOI
- Sun, 2012, The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA, PLoS One, 7, e43158, 10.1371/journal.pone.0043158 · DOI
- Wang, 2006, Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins, J Med Chem, 49, 6139, 10.1021/jm060460o · DOI · Paper page
- Billard, 2013, BH3 mimetics: status of the field and new developments, Mol Cancer Ther, 12, 1691, 10.1158/1535-7163.MCT-13-0058 · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Medina, 2016, Do not let death do us part: ‘find-me’ signals in communication between dying cells and the phagocytes, Cell Death Differ, 23, 979, 10.1038/cdd.2016.13 · DOI · Paper page
- Ricotta, 2013, Regorafenib for metastatic colorectal cancer, Lancet, 381, 1537, 10.1016/S0140-6736(13)60976-9 · doi:10.1016/s0140-6736(13)60976-9
- Del Poeta, 2016, Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia, Drugs Today, 52, 249, 10.1358/dot.2016.52.4.2470954 · DOI
- Konopleva, 2006, Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia, Cancer Cell, 10, 375, 10.1016/j.ccr.2006.10.006 · DOI · Paper page
- Tahir, 2007, Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737, Cancer Res, 67, 1176, 10.1158/0008-5472.CAN-06-2203 · DOI · Paper page
- van Delft, 2006, The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, 10, 389, 10.1016/j.ccr.2006.08.027 · DOI · Paper page
- Day, 2008, Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1, J Mol Biol, 380, 958, 10.1016/j.jmb.2008.05.071 · DOI · Paper page
- Youle, 2008, The BCL-2 protein family: opposing activities that mediate cell death, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308 · DOI · Paper page
- Friberg, 2013, Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design, J Med Chem, 56, 15, 10.1021/jm301448p · DOI · Paper page
- Pelz, 2016, Discovery of 2-Indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods, J Med Chem, 59, 2054, 10.1021/acs.jmedchem.5b01660 · DOI · Paper page
- Cohen, 2012, A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival, Chem Biol, 19, 1175, 10.1016/j.chembiol.2012.07.018 · DOI · Paper page
- Nguyen, 2007, Small molecule obatoclax (GX15–070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis, Proc Natl Acad Sci U S A, 104, 19512, 10.1073/pnas.0709443104 · DOI · Paper page
- Wei, 2011, An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins, Front Oncol, 1, 28, 10.3389/fonc.2011.00028 · DOI
Cited by
Zhu, L., & Xue, L. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15228018559434 · Cited by 192
MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J., Patil, D., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-021-04334-y · Cited by 29
Metadata
- Authors
- Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska-Coleska, Z., Zou, F., Yu, J., & Zhang, L.
- Venue
- Cancer Research
- Published
- 2017-04-30
- Volume
- 77
- Issue
- 9
- Pages
- 2512-2521
- ISSN
- 0008-5472
- 1538-7445
- Cited by
- 129
- References
- 9
- Language
- en
- Funders
- NIH (R01CA106348, R01CA172136, and R01CA203028, U01DK085570 and U19AI068021, R01CA149442)
- National Natural Science Foundation of China (81672942)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-3242
- The paper
- Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska-Coleska, Z., Zou, F., Yu, J., & Zhang, L. (2017). Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-3242
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.